Prevalence and Prognostic Significance of Heart Failure Stages
Top Cited Papers
- 27 March 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 115 (12) , 1563-1570
- https://doi.org/10.1161/circulationaha.106.666818
Abstract
Heart failure (HF) is a progressive disorder associated with frequent morbidity and mortality. An American Heart Association/American College of Cardiology staging classification of HF has been developed to emphasize early detection and prevention. The prevalence of HF stages and their association with mortality are unknown. We sought to estimate HF stage prevalence in the community and to measure the association of HF stages with mortality. A population-based, cross-sectional, random sample of 2029 Olmsted County, Minnesota, residents aged > or = 45 years was identified. Participants were classified by medical record review, symptom questionnaire, physical examination, and echocardiogram as follows: stage 0, healthy; stage A, HF risk factors; stage B, asymptomatic cardiac structural or functional abnormalities; stage C, HF symptoms; and stage D, severe HF. In the cohort, 32% were stage 0, 22% stage A, 34% stage B, 12% stage C, and 0.2% stage D. Mean B-type natriuretic peptide concentrations (in pg/mL) increased by stages: stage 0=26, stage A=32, stage B=53, stage C=137, and stage D=353. Survival at 5 years was 99% in stage 0, 97% in stage A, 96% in stage B, 75% in stage C, and 20% in stage D. The present study provides prevalence estimates and prognostic validation for HF staging in a community cohort. Of note, 56% of adults > or = 45 years of age were classified as being in stage A (risk factors) or B (asymptomatic ventricular dysfunction). HF staging underscores the magnitude of the population at risk for progression to overt HF.Keywords
This publication has 29 references indexed in Scilit:
- Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide in the General CommunityJournal of the American College of Cardiology, 2006
- Diastolic dysfunction and left atrial volumeJournal of the American College of Cardiology, 2005
- Plasma Brain Natriuretic Peptide to Detect Preclinical Ventricular Systolic or Diastolic DysfunctionCirculation, 2004
- Association of newer diastolic function parameters with age in healthy subjects: a population-based studyJournal of the American Society of Echocardiography, 2003
- Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study∗∗The views expressed in this study are those of the authors and do not necessarily reflect those of the Indian Health Service.The American Journal of Cardiology, 2000
- Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the framingham heart study)The American Journal of Cardiology, 1992
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyNew England Journal of Medicine, 1990
- Echocardiographic criteria for left ventricular hypertrophy: The Framingham heart studyThe American Journal of Cardiology, 1987
- International diagnostic criteria for acute myocardial infarction and acute strokeAmerican Heart Journal, 1984
- The Patient Record in EpidemiologyScientific American, 1981